Allogene Therapeutics ALLO Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $40.6M-23.0% | $61.98M-27.5% | $48.11M-21.8% | $62.62M-65.4% | $52.75M-14.0% | ||
| $236.58M-0.4% | $198.52M-8.6% | $214.38M-10.8% | $220.79M-19.4% | $237.59M-28.8% | ||
| $273.29M-6.3% | $257.75M-15.0% | $260.72M-14.4% | $282.66M-38.2% | $291.58M-26.3% | ||
| $70.02M-15.6% | $72.84M-15.4% | $75.9M-14.7% | $78.86M-14.4% | $82.99M-13.5% | ||
| $395.96M-22.1% | $415.91M-24.2% | $439.77M-25.4% | $470.59M-27.3% | $507.98M-13.4% | ||
| $4.93M-2.5% | $4.27M-20.8% | $3.7M-32.8% | $4.85M-62.5% | $5.06M-12.5% | ||
| $28.33M-5.6% | $32.51M-8.5% | $31.83M-2.3% | $31.68M-15.1% | $30.02M-2.8% | ||
| $117.08M-4.5% | $123.36M-2.5% | $124.44M-0.7% | $126.03M-4.4% | $122.59M-1.9% | ||
| 400M0.0% | 400M+188,579% | 400M0.0% | 400M0.0% | 400M0.0% | ||
| -$2.05B-9.2% | -$2.01B-10.5% | -$1.97B-12.0% | -$1.93B-14.0% | -$1.88B-15.5% | ||
| $278.88M-27.6% | $292.54M-30.7% | $315.33M-32.0% | $344.56M-33.1% | $385.39M-16.5% | ||
| $395.96M-22.1% | $415.91M-24.2% | $439.77M-25.4% | $470.59M-27.3% | $507.98M-13.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Allogene Therapeutics's total assets?
- Allogene Therapeutics (ALLO) holds $396.0M in total assets, down 22.1% year over year.
- How much debt does Allogene Therapeutics have?
- Allogene Therapeutics carries $81.1M in total debt against $278.9M of shareholders' equity, a debt-to-equity ratio of 0.29.
- How much cash does Allogene Therapeutics have?
- Allogene Therapeutics holds $40.6M in cash and equivalents.
- Can Allogene Therapeutics cover its short-term obligations?
- Its current ratio is 9.65 — current assets exceed current liabilities.
- Where does Allogene Therapeutics's balance sheet data come from?
- Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.